Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G9TY5A101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 4
|
9.9% |
5/15/2026
Event 3/31/2026
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y. Koh | 9.9% | ||
|
Great Point Partners, LLC
13G/A
Amendment 3
|
4.4% |
5/15/2026
Event 3/31/2026
|
|
| Great Point Partners, LLC | 4.4% | ||
| Dr. Jeffrey R. Jay, M.D. | 4.4% | ||
| Ms. Lillian Nordahl | 4.4% | ||
|
Suvretta Capital Management, LLC
13G/A
Amendment 3
|
9.9% |
5/12/2026
Event 3/31/2026
|
|
| Suvretta Capital Management, LLC | 9.9% | ||
| Averill Master Fund, Ltd. | 8.8% | ||
| Aaron Cowen | 9.9% | ||
| JPMorgan Chase & Co 13G/A Amendment 1 | 4.7% |
5/6/2026
Event 4/30/2026
|
|
|
AI Biotechnology LLC
13D/A
Amendment 1
|
18.2% |
3/2/2026
Event 2/26/2026
|
|
| AI Biotechnology LLC | 18.2% | ||
| Access Industries Holdings LLC | 18.2% | ||
| Access Industries Management, LLC | 18.2% | ||
| Len Blavatnik | 18.2% | ||
|
Great Point Partners, LLC
13G/A
Amendment 2
|
5.2% |
2/17/2026
Event 12/31/2025
|
|
| Great Point Partners, LLC | 5.2% | ||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||
| Ms. Lillian Nordahl | 5.2% | ||
|
Suvretta Capital Management, LLC
13G/A
Amendment 2
|
8.6% |
2/13/2026
Event 12/31/2025
|
|
| Suvretta Capital Management, LLC | 8.6% | ||
| Averill Master Fund, Ltd | 7.7% | ||
| Aaron Cowen | 8.6% | ||
|
Athanor Capital
13D
|
15.7% |
1/27/2026
Event 1/23/2026
|
|
| Athanor Capital | 15.7% | ||
| UGS Capital LLC | 15.7% | ||
|
Athanor Capital
13G
|
15.7% |
1/2/2026
Event 12/29/2025
|
|
| Athanor Capital | 15.7% | ||
| UGS Capital LLC | 15.7% | ||
|
Great Point Partners, LLC
13G/A
Amendment 1
|
5.9% |
11/14/2025
Event 9/30/2025
|
|
| Great Point Partners, LLC | 5.9% | ||
| Dr. Jeffrey R. Jay, M.D. | 5.9% | ||
| Ms. Lillian Nordahl | 5.9% | ||
|
Deep Track Capital, LP
13G/A
Amendment 4
|
0.4% |
11/14/2025
Event 9/30/2025
|
|
| Deep Track Capital, LP | 0.4% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 0.4% | ||
| David Kroin | 0.4% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y. Koh | 9.9% | ||
|
Deep Track Capital, LP
13G/A
Amendment 3
|
7.1% |
8/14/2025
Event 6/30/2025
|
|
| Deep Track Capital, LP | 7.1% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 7.1% | ||
| David Kroin | 7.1% | ||
| JPMorgan Chase & Co 13G | 7.5% |
7/16/2025
Event 6/30/2025
|
|
|
AI Biotechnology LLC
13D
|
19.9% |
5/28/2025
Event 5/21/2025
|
|
| AI Biotechnology LLC | 19.9% | ||
| Access Industries Holdings LLC | 19.9% | ||
| Access Industries Management, LLC | 19.9% | ||
| Len Blavatnik | 19.9% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 2
|
9.9% |
5/15/2025
Event 3/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y Koh | 9.9% | ||
|
Great Point Partners, LLC
13G
|
5.1% |
5/14/2025
Event 5/8/2025
|
|
| Great Point Partners, LLC | 5.1% | ||
| Dr. Jeffrey R. Jay, M.D. | 5.1% | ||
| Ms. Lillian Nordahl | 5.1% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 1
|
4.9% |
2/14/2025
Event 12/31/2024
|
|
| RA Capital Management, L.P. | 4.9% | ||
| Peter Kolchinsky | 4.9% | ||
| Rajeev Shah | 4.9% | ||
| RA Capital Healthcare Fund, L.P. | 4.9% | ||
|
Great Point Partners, LLC
13G/A
Amendment 3
|
4.9% |
2/14/2025
Event 12/31/2024
|
|
| Great Point Partners, LLC | 4.9% | ||
| Dr. Jeffrey R. Jay, M.D. | 4.9% | ||
| Ms. Lillian Nordahl | 4.9% | ||
|
ADAR1 Capital Management, LLC
13G/A
Amendment 1
|
3.2% |
2/14/2025
Event 12/31/2024
|
|
| ADAR1 Capital Management, LLC | 3.2% | ||
| ADAR1 Capital Management GP, LLC | 2.4% | ||
| Daniel Schneeberger | 3.2% | ||
| Pfizer Inc 13G/A Amendment 1 | 4.6% |
2/12/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 5.61 k | $23.3 k |
| 2026 Q2 | 99 | 72.9 M | $430 M |
| 2026 Q1 | 98 | 66.8 M | $396 M |
| 2025 Q4 | 81 | 44.9 M | $235 M |
| 2025 Q3 | 72 | 45.8 M | $198 M |
| 2025 Q2 | 66 | 35.3 M | $37.1 M |
| 2025 Q1 | 77 | 45.7 M | $59.0 M |
| 2024 Q4 | 94 | 42.9 M | $107 M |
| 2024 Q3 | 86 | 37.2 M | $151 M |
| 2024 Q2 | 60 | 33.0 M | $115 M |
| 2024 Q1 | 49 | 14.9 M | $37.7 M |
| 2023 Q4 | 49 | 15.3 M | $71.1 M |
| 2023 Q3 | 43 | 14.1 M | $93.3 M |
| 2023 Q2 | 40 | 12.8 M | $105 M |
| 2023 Q1 | 3 | 25.7 k | $24.7 k |